1. The role of polymorphism of the epidermal growth factor gene in the formation of severe manifestations of skin toxicity caused by the use of EGFR inhibitors
   Ekaterina V. Orlova et al, 2023, Russian Journal of Skin and Venereal Diseases CrossRef
2. Plasma D‐dimer and interleukin‐6 are associated with treatment response and progression‐free survival in advanced NSCLC patients on anti‐PD‐1 therapy
   Chong Chen et al, 2023, Cancer Medicine CrossRef
3. Significance of EGFR investigation in odontogenic keratocyst: a narrative review
   Valentina Vasiljevic et al, 2023, Molecular Biology Reports CrossRef
4. Adenovirus pneumonia mimicking osimertinib‐induced pneumonitis in a patient with advanced NSCLC with EGFR mutation: A case report
   Toru Imai et al, 2024, Thoracic Cancer CrossRef
5. Tumor-suppressive action of miR-30a-5p in lung adenocarcinoma correlates with ABL2 inhibition and PI3K/AKT pathway inactivation
   Yajun Miao et al, 2023, Clinical and Translational Oncology CrossRef
6. Influence of Smoking Habits on the Efficacy of EGFR-TKI Therapy in Patients with Advanced NSCLC: A Systematic Review and Meta-Analysis
   Zexun Mo et al, 2023, Clinical Medicine Insights: Oncology CrossRef
7. Long‑term survival of a patient with advanced lung cancer treated with targeted therapy and anti‑PD‑1 immunotherapy as multi‑line therapy: A case report
   Tianhao Guo et al, 2023, Oncology Letters CrossRef
8. Contribution of immune cells in synergistic anti-tumor effect of ablation and immunotherapy
   Ningning He et al, 2024, Translational Oncology CrossRef
9. Depletion of enhancer zeste homolog 2 (EZH2) directs transcription factors associated with T cell differentiation through epigenetic regulation of Yin Yang 1(YY1) in combating non-small cell lung cancer (NSCLC)
   Nikhil Chandnani et al, 2023, Medical Oncology CrossRef